CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 12 enrolled
Drug / intervention
Raltegravirdrug
Likely dose
Raltegravir 600 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03667547
NCT03667547Phase 4Completed
CompareCT.gov

An Open-label Single Oral Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-0518 1200 mg (600 mg Tablet × 2) in Healthy Japanese Male Participants

Merck Sharp & Dohme LLC·interventional·Posted Sep 12, 2018·Updated Oct 2, 2019

In Brief

A Phase 4 clinical trial evaluating Raltegravir for Human Immunodeficiency Virus (HIV) Infection. Completed, enrolled 12 participants across 1 site.

Detailed Summary

This study is designed to evaluate safety, tolerability, and pharmacokinetics of a single 1200-mg dose of raltegravir (MK-0518, ISENTRESS®) in healthy Japanese male participants.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHuman Immunodeficiency Virus (HIV) Infection
CountriesJapan
Collaborators--

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedSep 12, 2018
Enrollment StartSep 27, 2018
Primary CompletionOct 23, 2018
TodayJul 2, 2026
Enrollment to primary: 26 daysPosted 7.8 years ago

Interventions

Raltegravirdrug

Raltegravir 600 mg tablet